It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bacterial ribosome rescue pathways that remove ribosomes stalled on mRNAs during translation have been proposed as novel antibiotic targets because they are essential in bacteria and are not conserved in humans. We previously reported the discovery of a family of acylaminooxadiazoles that selectively inhibit trans-translation, the main ribosome rescue pathway in bacteria. Here, we report optimization of the pharmacokinetic and antibiotic properties of the acylaminooxadiazoles, producing MBX-4132, which clears multiple-drug resistant Neisseria gonorrhoeae infection in mice after a single oral dose. Single particle cryogenic-EM studies of non-stop ribosomes show that acylaminooxadiazoles bind to a unique site near the peptidyl-transfer center and significantly alter the conformation of ribosomal protein bL27, suggesting a novel mechanism for specific inhibition of trans-translation by these molecules. These results show that trans-translation is a viable therapeutic target and reveal a new conformation within the bacterial ribosome that may be critical for ribosome rescue pathways.
Antibiotic-resistant bacterial pathogens pose a substantial threat to human health. Here, aided by structural analyses, the authors describe the molecular mechanism behind the activity of a series of compounds that inhibit trans-translation and are effective in eradicating N. gonorrhoeae infection in mice.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Microbiotix, Inc. One Innovation Dr., Worcester, USA (GRID:grid.280642.a) (ISNI:0000 0004 1796 7154)
2 Florida State University, Department of Chemistry and Biochemistry, Tallahassee, USA (GRID:grid.255986.5) (ISNI:0000 0004 0472 0419)
3 Emory University School of Medicine, Department of Biochemistry and Emory Antibiotic Resistance Center, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
4 Uniformed Services University, Department of Microbiology and Immunology, Bethesda, USA (GRID:grid.265436.0) (ISNI:0000 0001 0421 5525)
5 Emory University School of Medicine, Department of Biochemistry and Emory Antibiotic Resistance Center, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University, Molecular & Systems Pharmacology Graduate Program, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
6 Penn State University, Department of Biochemistry & Molecular Biology, University Park, USA (GRID:grid.29857.31) (ISNI:0000 0001 2097 4281)
7 Florida State University, Department of Chemistry and Biochemistry, Tallahassee, USA (GRID:grid.255986.5) (ISNI:0000 0004 0472 0419); Florida State University, Institute of Molecular Biophysics, Tallahassee, USA (GRID:grid.255986.5) (ISNI:0000 0004 0472 0419)